CAR‐T cell therapy: Advancements in clinical applications and laboratory testing

CAR‐T cell therapy is a representative form of adoptive cancer immunotherapy. This review summarizes recent advances in CAR‐T cell therapy and associated laboratory tests for clinical practice. CAR‐T cell therapy is designed to enhance T cell immunity, distinguishing it from conventional cancer treatments such as surgery, chemotherapy, or radiotherapy. It has shown significant efficacy in hematologic malignancies but continues to yield limited results in many solid tumors. Intensive research efforts are underway to develop more potent CAR‐T cells and to uncover mechanisms of resistance. For broader clinical application, the development of reliable biomarkers and standardized management guidelines is essential. These include criteria for evaluating leukapheresis success, tests for CAR‐T efficacy, biomarkers for prognosis or resistance, and laboratory assays for detecting side effects and toxicity. Recent progress in laboratory diagnostics in the clinical field will play a pivotal role in optimizing patient management in the era of CAR‐T cell therapy.

• Publication year

  2026

• Venue

  International Journal of Cancer

• Publication date

  2026-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.70348PMID 41579019
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The next innovations in chimeric antigen receptor T cell immunotherapies for cancer.

  2025cited by this paper
• CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights

  2025cited by this paper
• Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies

  2025cited by this paper
• Neurotoxicity associated with chimeric antigen receptor T-cell therapy.

  2025cited by this paper
• Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma

  2024influential reference
• Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

  2024cited by this paper
• Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.

  2024cited by this paper
• Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

  2024cited by this paper
• Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines

  2024cited by this paper
• ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy.

  2024cited by this paper
• Need for Standardization of Cytokine Profiling in CAR T-Cell Therapy.

  2024cited by this paper
• Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood

  2024cited by this paper
• Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy

  2024cited by this paper
• Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B-Cell Lymphoma Patients.

  2024cited by this paper
• CAR-T cell manufacturing: Major process parameters and next-generation strategies

  2024cited by this paper
• Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

  2024cited by this paper
• Approved CAR-T therapies have reproducible efficacy and safety in clinical practice

  2024cited by this paper
• CAR T CELL THERAPY

  2024cited by this paper
• CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

  2023cited by this paper
• Estimation of eligibility for and response to CAR-T therapy in the United States

  2023cited by this paper
• Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML

  2023influential reference
• Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

  2023cited by this paper
• Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia.

  2023cited by this paper
• Medical diagnostic value of digital PCR (dPCR): A systematic review

  2023cited by this paper
• Ferritin and procalcitonin serve as discriminative inflammatory biomarkers and can predict the prognosis of severe fever with thrombocytopenia syndrome in its early stages

  2023cited by this paper
• Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

  2023cited by this paper
• Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737-2746.

  2023cited by this paper
• Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy

  2023cited by this paper
• CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift?

  2022cited by this paper
• Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

  2022cited by this paper
• Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients

  2022cited by this paper
• T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy

  2022cited by this paper
• Liquid biopsy: current technology and clinical applications

  2022cited by this paper
• CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

  2022cited by this paper
• Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside

  2022cited by this paper
• Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations

  2022cited by this paper
• Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.

  2022cited by this paper
• CAR T-Cell Therapy in the Older Person: Indications and Risks

  2022influential reference
• Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians

  2022cited by this paper
• Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells

  2022cited by this paper
• Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse.

  2021influential reference
• Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma

  2021cited by this paper
• The Application of Nanobody in CAR-T Therapy

  2021cited by this paper
• Navigating CAR-T cells through the solid-tumour microenvironment

  2021cited by this paper
• CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.

  2021cited by this paper
• CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

  2021cited by this paper
• Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021influential reference
• 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells

  2021cited by this paper
• Hypogammaglobulinemia after Chimeric Antigen Receptor (CAR) T-cell therapy: characteristics, management, and future directions.

  2021cited by this paper
• 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.

  2021cited by this paper
• Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations.

  2021cited by this paper
• Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR

  2021cited by this paper
• Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement.

  2020cited by this paper
• ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

  2020cited by this paper
• Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies.

  2020cited by this paper
• Monitoring CAR T‐cells using flow cytometry

  2020cited by this paper
• Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials.

  2020cited by this paper
• Important aspects of T‐cell collection by apheresis for manufacturing chimeric antigen receptor T cells

  2020cited by this paper
• Identification of neurotoxicity after chimeric antigen receptor (CAR) T-cell infusion without deterioration in the immune effector cell encephalopathy (ICE) score.

  2020cited by this paper
• Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients

  2020cited by this paper
• CAR-T cell therapy for lung cancer: a promising but challenging future

  2020cited by this paper
• Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL

  2020cited by this paper
• Cytokine release syndrome in severe COVID-19

  2020cited by this paper
• KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

  2020cited by this paper
• A brief history of CAR-T cells: from laboratory to the bedside

  2020cited by this paper
• Response Assessment and Post–CAR T-Cell Therapy Management

  2020cited by this paper
• Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

  2020cited by this paper
• FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview

  2020cited by this paper
• Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction.

  2020cited by this paper
• Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020influential reference
• Early and late hematologic toxicity following CD19 CAR-T cells

  2019cited by this paper
• Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

  2019cited by this paper
• Current challenges and emerging opportunities of CAR-T cell therapies.

  2019cited by this paper
• Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity.

  2019cited by this paper
• Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

  2019cited by this paper
• Subcutaneous immunoglobulin replacement following CD19‐specific chimeric antigen receptor T‐cell therapy for B‐cell acute lymphoblastic leukemia in pediatric patients

  2019cited by this paper
• Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

  2019cited by this paper
• Current Progress in CAR-T Cell Therapy for Solid Tumors

  2019cited by this paper
• Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS

  2019cited by this paper
• Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

  2019cited by this paper
• Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

  2019cited by this paper
• ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

  2019cited by this paper
• Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.

  2019cited by this paper
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

  2018cited by this paper
• ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.

  2018cited by this paper
• Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

  2018cited by this paper
• Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

  2018cited by this paper
• Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

  2018cited by this paper
• Lymphocyte apheresis for chimeric antigen receptor T‐cell manufacturing in children and young adults with leukemia and neuroblastoma

  2018cited by this paper
• Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

  2017cited by this paper
• Systemic therapy for esophagogastric cancer: targeted therapies.

  2017cited by this paper
• Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

  2017cited by this paper
• Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

  2016cited by this paper
• Toxicity and management in CAR T-cell therapy

  2016cited by this paper
• Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

  2015cited by this paper
• Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

  2014cited by this paper
• Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

  2014cited by this paper

• No citing papers are available for this paper.